A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

Part of paid clinical trials in Houston, Texas.

Sponsor
The University of Texas Health Science Center, Houston
Study ID
NCT07770646
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Axial Spondyloarthritis (AxSpA)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab (IL-17i ) — DRUG
    Secukinumab is a fully humananized monoclonal antibody targeting interleukin-17A. Secukinumab will be given as a prefilled syringe or autoinjector for subcutaneous administration. Dosing is 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 followed by 150mg every 4 weeks thereafter for a total of 16 weeks.
  • Upadacitinib (JAKi) — DRUG
    Upadacitinib is an oral selective inhibitor of janus kinase 1 (JAK1). Participants will take upadacitinib 15mg orally once daily for 16 weeks.

Study Details

The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi

Key Dates

First listed
Aug 18, 2026
Start date
Sep 14, 2026
Status verified
Aug 2026
Primary completion
Sep 15, 2028
Completion
Sep 15, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Secukinumab (IL-17i )
  • Experimental: Upadacitinib (JAKi)

Primary Outcome Measure

Feasibility as determined by enrollment of ≥60% of eligible patients [ Time Frame: end of treatment (week 16) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas health Science Center at HoustonHoustonTexas77030
Savannah Bowman, MD
[email protected]
(713) 500-6883
Mark C Hwang
[email protected]
(713) 500-6597

Find similar trials in Houston, TX

By research site
The University of Texas health Science Center at Houston· Houston, TX